BMEA

Biomea Fusion, Inc.

• TipRanks·6d ago

  Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes

• TipRanks·6d ago

  Biomea Fusion Advances Mid‑Stage Diabetes Trial, Adding a New Angle to the BMEA Investment Story

• Reuters·03/31 21:08

  Biomea Fusion doses first patient in Phase II icovamenib trials for type 2 diabetes

• TipRanks·03/31 13:30

  Analysts Are Bullish on These Healthcare Stocks: Unicycive Therapeutics (UNCY), Biomea Fusion (BMEA)

• TipRanks·03/31 11:24

  Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials

• Benzinga·03/31 11:07

  Biomea Fusion Starts New Trials to Test Diabetes Drug in Patients

• Reuters·03/31 11:00

  BIOMEA FUSION INC: TOPLINE 26-WEEK PRIMARY ENDPOINT DATA FROM BOTH PHASE II STUDIES ANTICIPATED 4Q 2026

• Dow Jones·03/27 15:22

  Biomea Fusion Price Target Raised to $7.00/Share From $6.00 by Citigroup

• Dow Jones·03/27 15:22

  Biomea Fusion Is Maintained at Buy by Citigroup

• Benzinga·03/27 15:12

  Citigroup Maintains Buy on Biomea Fusion, Raises Price Target to $7

• TipRanks·03/27 10:32

  Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’

• TipRanks·03/25 16:00

  Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Maze Therapeutics, Inc. (MAZE)

• Dow Jones·03/25 15:18

  Biomea Fusion Is Maintained at Buy by D. Boral Capital

• Dow Jones·03/25 15:18

  Biomea Fusion Price Target Maintained With a $12.00/Share by D. Boral Capital